中枢性嗜睡障碍（PROM-CDH）患者报告的结果测量：发展和验证

IF 3.4 2区医学 Q1 CLINICAL NEUROLOGY

Sleep medicine Pub Date : 2025-05-19 DOI:10.1016/j.sleep.2025.106589

Bijlenga Denise , De Boer Josephine , Fronczek Rolf , Tiemensma Jitske , Lammers Gert Jan

{"title":"中枢性嗜睡障碍（PROM-CDH）患者报告的结果测量：发展和验证","authors":"Bijlenga Denise , De Boer Josephine , Fronczek Rolf , Tiemensma Jitske , Lammers Gert Jan","doi":"10.1016/j.sleep.2025.106589","DOIUrl":null,"url":null,"abstract":"<div><h3>Study objectives</h3><div>Central disorders of hypersomnolence (CDH) have a major impact on patients' quality of life (QoL). We developed and validated a disease-specific patient-reported outcome measure (PROM) to measure QoL in CDH: the PROM-CDH, for adults with narcolepsy types 1 and 2 (NT1 and NT2), and idiopathic hypersomnia (IH).</div></div><div><h3>Methods</h3><div>The developmental process involved focus groups and interviews with adults with CDH (n = 27), family members (n = 8) and sleep medicine specialists (n = 5). In the quantitative evaluation, the draft version of the PROM-CDH, together with the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), ADHD rating scale (ADHD-RS) and the 36-item Short Form (SF-36) were filled out online by N = 369 patients with (suspected) CDH.</div></div><div><h3>Results</h3><div>Internal consistency was good for the total group and within diagnostic groups (all Cronbach's α > .8). Age was positively (β = .11; p = .003), and female gender (β = −3.67; p = .002), comorbid sleep apnea (β = −4.77; p = .005), and depression (β = −12.71; p < .001) were negatively associated with the PROM-CDH score. Exploratory and confirmatory factor analyses resulted in five subscales. Convergent validity showed highest correlation between the PROM-CDH total score and HADS Depression (r = −.71; p < .01); and the SF-36 subscales Emotional wellbeing (r = .65; p < .01) and Energy/fatigue (r = .71; p < .01). Additional adjustments including content validity in consensus rounds resulted in the final PROM-CDH (version 1, 2023).</div></div><div><h3>Conclusions</h3><div>The PROM-CDH has high potential in clinical practice for patients with CDH, to support clinical care, as an important outcome in clinical trials, and as a sleep care quality indicator. Further international validation is ongoing, and it is freely available in multiple languages.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"133 ","pages":"Article 106589"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation\",\"authors\":\"Bijlenga Denise , De Boer Josephine , Fronczek Rolf , Tiemensma Jitske , Lammers Gert Jan\",\"doi\":\"10.1016/j.sleep.2025.106589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Study objectives</h3><div>Central disorders of hypersomnolence (CDH) have a major impact on patients' quality of life (QoL). We developed and validated a disease-specific patient-reported outcome measure (PROM) to measure QoL in CDH: the PROM-CDH, for adults with narcolepsy types 1 and 2 (NT1 and NT2), and idiopathic hypersomnia (IH).</div></div><div><h3>Methods</h3><div>The developmental process involved focus groups and interviews with adults with CDH (n = 27), family members (n = 8) and sleep medicine specialists (n = 5). In the quantitative evaluation, the draft version of the PROM-CDH, together with the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), ADHD rating scale (ADHD-RS) and the 36-item Short Form (SF-36) were filled out online by N = 369 patients with (suspected) CDH.</div></div><div><h3>Results</h3><div>Internal consistency was good for the total group and within diagnostic groups (all Cronbach's α > .8). Age was positively (β = .11; p = .003), and female gender (β = −3.67; p = .002), comorbid sleep apnea (β = −4.77; p = .005), and depression (β = −12.71; p < .001) were negatively associated with the PROM-CDH score. Exploratory and confirmatory factor analyses resulted in five subscales. Convergent validity showed highest correlation between the PROM-CDH total score and HADS Depression (r = −.71; p < .01); and the SF-36 subscales Emotional wellbeing (r = .65; p < .01) and Energy/fatigue (r = .71; p < .01). Additional adjustments including content validity in consensus rounds resulted in the final PROM-CDH (version 1, 2023).</div></div><div><h3>Conclusions</h3><div>The PROM-CDH has high potential in clinical practice for patients with CDH, to support clinical care, as an important outcome in clinical trials, and as a sleep care quality indicator. Further international validation is ongoing, and it is freely available in multiple languages.</div></div>\",\"PeriodicalId\":21874,\"journal\":{\"name\":\"Sleep medicine\",\"volume\":\"133 \",\"pages\":\"Article 106589\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1389945725002643\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1389945725002643","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

研究目的中枢性嗜睡障碍（CDH）对患者的生活质量（QoL）有重要影响。我们开发并验证了一种疾病特异性的患者报告结果测量（PROM）来测量CDH的生活质量：PROM-CDH，用于患有1型和2型发作性睡病（NT1和NT2）和特发性嗜睡症（IH）的成人。方法采用焦点小组和访谈法，对成人CDH患者（27例）、家庭成员（8例）和睡眠医学专家（5例）进行访谈。定量评估中，对369例（疑似）CDH患者在线填写promm -CDH初稿、Epworth嗜睡量表（ESS）、疲劳严重程度量表（FSS）、医院焦虑抑郁量表（HADS）、ADHD评定量表（ADHD- rs）和36项短表（SF-36）。结果总组和诊断组内部一致性良好(所有Cronbach's α >；8)。年龄呈正相关(β = 0.11；P = 0.003)，女性(β = - 3.67；P = .002)，共病睡眠呼吸暂停(β = - 4.77；P = 0.005)，抑郁(β = - 12.71；p & lt;.001)与PROM-CDH评分呈负相关。探索性和验证性因素分析产生五个子量表。收敛效度显示，PROM-CDH总分与HADS抑郁的相关性最高(r = - 0.71；p & lt;. 01);SF-36子量表情绪幸福感(r = 0.65；p & lt;.01)和能量/疲劳(r = .71；p & lt;. 01)。额外的调整包括共识轮中的内容有效性，最终形成了PROM-CDH（2023年版本1）。结论PROM-CDH作为临床试验的重要结果，作为睡眠护理质量的指标，在临床实践中具有较高的应用潜力，可支持临床护理。进一步的国际验证正在进行中，并以多种语言免费提供。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation

查看原文本刊更多论文

Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation

Study objectives

Central disorders of hypersomnolence (CDH) have a major impact on patients' quality of life (QoL). We developed and validated a disease-specific patient-reported outcome measure (PROM) to measure QoL in CDH: the PROM-CDH, for adults with narcolepsy types 1 and 2 (NT1 and NT2), and idiopathic hypersomnia (IH).

Methods

The developmental process involved focus groups and interviews with adults with CDH (n = 27), family members (n = 8) and sleep medicine specialists (n = 5). In the quantitative evaluation, the draft version of the PROM-CDH, together with the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), ADHD rating scale (ADHD-RS) and the 36-item Short Form (SF-36) were filled out online by N = 369 patients with (suspected) CDH.

Results

Internal consistency was good for the total group and within diagnostic groups (all Cronbach's α > .8). Age was positively (β = .11; p = .003), and female gender (β = −3.67; p = .002), comorbid sleep apnea (β = −4.77; p = .005), and depression (β = −12.71; p < .001) were negatively associated with the PROM-CDH score. Exploratory and confirmatory factor analyses resulted in five subscales. Convergent validity showed highest correlation between the PROM-CDH total score and HADS Depression (r = −.71; p < .01); and the SF-36 subscales Emotional wellbeing (r = .65; p < .01) and Energy/fatigue (r = .71; p < .01). Additional adjustments including content validity in consensus rounds resulted in the final PROM-CDH (version 1, 2023).

Conclusions

The PROM-CDH has high potential in clinical practice for patients with CDH, to support clinical care, as an important outcome in clinical trials, and as a sleep care quality indicator. Further international validation is ongoing, and it is freely available in multiple languages.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sleep medicine 医学-临床神经学

CiteScore

8.40

自引率

6.20%

发文量

1060

审稿时长

49 days

期刊介绍： Sleep Medicine aims to be a journal no one involved in clinical sleep medicine can do without. A journal primarily focussing on the human aspects of sleep, integrating the various disciplines that are involved in sleep medicine: neurology, clinical neurophysiology, internal medicine (particularly pulmonology and cardiology), psychology, psychiatry, sleep technology, pediatrics, neurosurgery, otorhinolaryngology, and dentistry. The journal publishes the following types of articles: Reviews (also intended as a way to bridge the gap between basic sleep research and clinical relevance); Original Research Articles; Full-length articles; Brief communications; Controversies; Case reports; Letters to the Editor; Journal search and commentaries; Book reviews; Meeting announcements; Listing of relevant organisations plus web sites.